ReviewBMB reports2014
Revisiting PPARγ as a target for the treatment of metabolic disorders.
Review in BMB reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 128 citations in OpenAlex.
- A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis.Journal of cachexia, sarcopenia and muscle · 2024Trial
- Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.Journal of atherosclerosis and thrombosis · 2023Trial
- Design, Synthesis and Antihyperglycemic/Antilipidemic Activities of Quinoline-thiazolidine-2,4-dione Hybrid.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Network pharmacology and molecular simulation insights into the anti-diabetic and anti-inflammatory mechanisms of Ricinus communis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pioglitazone Mitigates Arsenic-Induced Cardiotoxicity via Lipid Metabolism: Network Pharmacology and Molecular Docking Approach.Cardiovascular toxicology · 2026Article
- PPAR-δ is a potential modulator of central carbon metabolism in human adipocytes.Bioinformation · 2026Article
- mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes.The pharmacogenomics journal · 2025Article
- Impact of Rosiglitazone on Subdermal Adipose Tissue Growth and Lipid Droplet Formation: An In Vitro and In Vivo Study.Aesthetic plastic surgery · 2025Article
- Targeting mitochondrial transporters and metabolic reprogramming for disease treatment.Journal of translational medicine · 2025Review
- Myeloperoxidase impacts vascular function by altering perivascular adipocytes' secretome and phenotype in obesity.Cell reports. Medicine · 2025Article
- Role of Non-Coding RNAs in White and Brown Adipose Tissue Differentiation and Development.Non-coding RNA · 2025Review
- L-Fucose-Rich Sulfated Glycans from Edible Brown Seaweed: A Promising Functional Food for Obesity and Energy Expenditure Improvement.International journal of molecular sciences · 2024Article
- In Silico Identification of Peptides with PPARγ Antagonism in Protein Hydrolysate from Rice (Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Impact of Nutrient Intake and Metabolic Wastes during Pregnancy on Offspring Hypertension: Challenges and Future Opportunities.Metabolites · 2023Review
- Novel targets for potential therapeutic use in Diabetes mellitus.Diabetology & metabolic syndrome · 2023Review
- Deletion of Spinophilin Promotes White Adipocyte Browning.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Diabetes and diabesity in the view of proteomics, drug, and plant-derived remedies.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Review
- Quercetin-3-Revista brasileira de farmacognosia : orgao oficial da Sociedade Brasileira de Farmacognosia · 2023Article
- PPARγ (Peroxisome Proliferator-Activated Receptor γ) Deacetylation Suppresses Aging-Associated Atherosclerosis and Hypercholesterolemia.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the prevalence of obesity has increased explosively over the last several decades, associated metabolic disorders, including type 2 diabetes, dyslipidemia, hypertension, and cardiovascular diseases, have been also increased. Thus, new strategies for preventing and treating them are needed. The nuclear peroxisome proliferator-activated receptors (PPARs) are involved fundamentally in regulating energy homeostasis; thus, they have been considered attractive drug targets for addressing metabolic disorders. Among the PPARs, PPARγ is a master regulator of gene expression for metabolism, inflammation, and other pathways in many cell types, especially adipocytes. It is a physiological receptor of the potent anti-diabetic drugs of the thiazolidinediones (TZDs) class, including rosiglitazone (Avandia). However, TZDs have undesirable and severe side effects, such as weight gain, fluid retention, and cardiovascular dysfunction. Recently, many reports have suggested that PPARγ could be modulated by post-translational modifications (PTMs), and modulation of PTM has been considered as novel approaches for treating metabolic disorders with fewer side effects than the TZDs. In this review, we discuss how PTM of PPARγ may be regulated and issues to be considered in making novel anti-diabetic drugs that can modulate the PTM of PPARγ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.